The combination of artificial intelligence and genome sequencing could significantly accelerate the development of precision medicine, according to researchers at the New York Genome Center (NYGC), The Rockefeller University, and IBM. Using the skills of IBM Watson, an artificial intelligence computer program, to examine complete genome sequencing data, researchers were able to analyze more genomic variants in less time than with other methods. The automated platform took ten minutes to provide a report containing potentially useful genomic information. The same task, performed by doctors, would have taken about 160 hours.
Conducted from 2015 to 2016, the study was conducted with a beta version of IBM Watson for Oncology, which has since been widely distributed. IBM has announced that its oncology platform has been clinically consistent with cancer diagnoses in some 93% of cases. “Our partnership has explored cutting-edge challenges and opportunities to harness genomics to help cancer patients,“ said researchers at IBM and the New York Genome Center, who worked closely together.
In the face of IBM, giants like Google and Microsoft also aspire to become leaders in artificial intelligence, as well as academia. They develop a number of algorithms that can identify malignant diseases and predict the evolution of some of them.